Supernus beats, affirms guidance, strong performance of Qelbree, GOCOVRI, ZURZUVAE, ONAPGO

 

Supernus Pharmaceuticals Inc reports fiscal Q1 2026 results with non-GAAP EPS $0.60 (+37% YoY) and revenue $207.7M (+39% YoY), beats EPS and revenue estimates

• Company reported GAAP loss per share of $0.04 for Q1 2026 despite strong revenue growth.
• Q1 2026 adjusted EPS was $0.59, reflecting improved profitability compared with the prior year.
• Quarter includes $20M milestone payment from Shionogi, significantly contributing to higher Q1 2026 revenue.
• Revenue growth was driven by strong performance of Qelbree, GOCOVRI, ZURZUVAE and ONAPGO during the quarter.
• Company reiterated full-year 2026 guidance, maintaining previously communicated revenue and profitability outlook.

https://finviz.com/quote?t=SUPN&p=d